PIC/S Committee has Adopted a Guide on Good Distribution Practice
The PIC/S Committee has adopted a Guide on Good Distribution Practice (GDP), which will enter into force on 1st June 2014. The PIC/S GDP Guide is based on the EU GDP Guide.
The PIC/S GDP Guide is a non-binding guidance document because PIC/S is not a regulatory authority in the sense of the competent authorities in the EU and the regulatory authorities in the US, Canada, Australia and Japan.
Each of the competent authority PIC/S members will make the decision regarding whether the guideline is to be implemented and enforced. Several regulatory authorities outside of the EU are members of PIC/S including the US, Canada, Japan and Australia. How this will be applied by those authorities is unknown at this time.
While the PIC/S guideline is based upon the EU GDP Guide and Chapters 1 through 9 have the same structure as the EU guideline, the following differences are noted with regard to the PIC/S GDP Guideline:
• EU specific references have been removed
• Import activities are included
• “Responsible Person” is replaced by designated responsible person(s)
• Contains more references to risk management throughout
• Additional reference are made to record(s)/procedure(s)s that should be maintained
• Batch/expiry guidance is based upon national legislation
• Contains more general requirements for import/export (not EU specific)
Includes more detail on actions taken upon identification of falsified medicines, including recall guidelines
• Does not contain a chapter on Brokers as in the EU Guide
• Lists additional glossary terms; including temperature, with defined ranges.
To view or download the PIC/S GDP Guidance, click here
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...